Johnson & Johnson's Crucell is officially out of the cholera space, and France's Valneva is in. And that means it's Valneva that's about to inherit some hefty competition that's coming up through its rivals' pipelines.
Another Big Pharma player is joining the hustle toward an Ebola vaccine as the death toll surpasses 1,900 victims, eclipsing the total number of people who died from the disease in all previous outbreaks combined.
PaxVax isn't just a vaccine developer anymore. The company is moving into the vaccines market with the pickup of a typhoid vaccine from Johnson & Johnson subsidiary Crucell, locking up $62 million in financing in the process.
Redwood City, CA-based PaxVax has nailed down up to $50 million in debt financing and $12 million in a Series B venture funding extension to complete the acquisition of Crucell's oral typhoid vaccine Vivotif and the ongoing Phase III study of its cholera vaccine candidate, PXVX0200.
An Indian medical ethics journal has criticized the World Health Organization for promoting the use of a Crucell vaccine that has been suspended in other countries.
Looks like Johnson & Johnson hit a roadblock in developing three experimental products the company acquired as part of its takeover of Dutch vaccine maker Crucell.
Crucell, the vaccines arm of Johnson & Johnson, suspended a delivery of 2.36 million seasonal flu vaccine doses to Italy, Reuters reports.
A joint venture marrying the protein and antibody development technology of Crucell with the manufacturing knowhow of Royal DSM has collapsed.
Scientists for the first time have successfully used a vaccine to protect monkeys from contracting their version of the AIDS virus. Johnson & Johnson ($J&J;) subsidiary Crucell NV of the
A new AIDS vaccine that combines two experimental therapies has shown promise in monkeys. The animals were given a vaccine developed by Johnson & Johnson ($JNJ) subsidiary Crucell combined with a...